The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

[1]  T. Gajewski,et al.  New perspectives on type I IFNs in cancer. , 2015, Cytokine & growth factor reviews.

[2]  D. Lawson,et al.  Role of Radiation Therapy as Immune Activator in the Era of Modern Immunotherapy for Metastatic Malignant Melanoma , 2015, American journal of clinical oncology.

[3]  J. McCubrey,et al.  Current treatment strategies for inhibiting mTOR in cancer. , 2015, Trends in pharmacological sciences.

[4]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[5]  J. Wolchok,et al.  Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 , 2015, Cell Research.

[6]  S. Chia,et al.  Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer. , 2015, Current oncology.

[7]  D. Zamarin,et al.  Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations , 2015 .

[8]  Hidde L. Ploegh,et al.  CEACAM1 regulates TIM-3-mediated tolerance and exhaustion , 2014, Nature.

[9]  Kristen N. Pollizzi,et al.  Regulation of T cells by mTOR: the known knowns and the known unknowns. , 2015, Trends in immunology.

[10]  S. Siva,et al.  Abscopal effects of radiation therapy: a clinical review for the radiobiologist. , 2015, Cancer letters.

[11]  J. Wolchok,et al.  Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer , 2014, Molecular therapy oncolytics.

[12]  J. Hackney,et al.  The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. , 2014, Cancer cell.

[13]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[14]  P. Hwu,et al.  Manipulating the Tumor Microenvironment Ex Vivo for Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy , 2014, Clinical Cancer Research.

[15]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[16]  V. Kuchroo,et al.  Mechanisms of TIGIT-driven immune suppression in cancer , 2014, Journal of Immunotherapy for Cancer.

[17]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[18]  R. Ferris,et al.  Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion , 2014, The Journal of Immunology.

[19]  I. Svane,et al.  Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? , 2014, Cancer Immunology, Immunotherapy.

[20]  D. Durden,et al.  A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis , 2014, Molecular Cancer Research.

[21]  J. Berzofsky,et al.  Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway , 2014, Cancer Immunology Research.

[22]  S. Tykodi.  PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence , 2014, OncoTargets and therapy.

[23]  P. Selvaraj,et al.  Cancer CARtography: charting out a new approach to cancer immunotherapy. , 2014, Immunotherapy.

[24]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[25]  G. Dranoff,et al.  OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy , 2014, Immunology and cell biology.

[26]  P. Ascierto,et al.  Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Rosenberg.  IL-2: The First Effective Immunotherapy for Human Cancer , 2014, The Journal of Immunology.

[28]  Dalya R. Soond,et al.  Inactivation of the PI3K p110δ breaks regulatory T cell-mediated immune tolerance to cancer , 2014, Nature.

[29]  E. Gilson,et al.  The metabolic checkpoint kinase mTOR is essential for interleukin-15 signaling during NK cell development and activation , 2014, Nature Immunology.

[30]  Siok-Keen Tey.  Adoptive T-cell therapy: adverse events and safety switches , 2014, Clinical & translational immunology.

[31]  J. Nemunaitis,et al.  CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma. , 2014 .

[32]  G. Gibney,et al.  Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. , 2014 .

[33]  G. Linette,et al.  Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM). , 2014 .

[34]  I. Puzanov,et al.  Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. , 2014 .

[35]  C. Ziegler,et al.  Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes , 2014, Cancer Immunology Research.

[36]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[37]  P. Darcy,et al.  Clinical application of genetically modified T cells in cancer therapy , 2014, Clinical & translational immunology.

[38]  J. Wolchok,et al.  Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy , 2014, Journal of Immunotherapy for Cancer.

[39]  D. Bartlett,et al.  Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity , 2014, Front. Oncol..

[40]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[41]  J. Wolchok,et al.  Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody , 2014, Science Translational Medicine.

[42]  R. Harvey.  Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer , 2014, Clinical pharmacology and therapeutics.

[43]  A. Luster,et al.  Chemokines and chemokine receptors: positioning cells for host defense and immunity. , 2014, Annual review of immunology.

[44]  B. Vanhaesebroeck,et al.  PI3Kδ inhibition hits a sensitive spot in B cell malignancies. , 2014, Cancer cell.

[45]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[46]  J. Wolchok,et al.  Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy , 2014, Science Translational Medicine.

[47]  B. Kwon,et al.  4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy , 2014, BMB reports.

[48]  H. Koblish,et al.  Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[49]  V. Kuchroo,et al.  Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade , 2014, Cancer Immunology Research.

[50]  T. Karrison,et al.  Adoptively Transferred Immune T Cells Eradicate Established Tumors despite Cancer-Induced Immune Suppression , 2014, The Journal of Immunology.

[51]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[52]  Teruhiko Yoshida,et al.  Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer , 2014, Cancer science.

[53]  N. Restifo,et al.  Uncoupling T‐cell expansion from effector differentiation in cell‐based immunotherapy , 2014, Immunological reviews.

[54]  S. Rosenberg,et al.  Exploiting the curative potential of adoptive T‐cell therapy for cancer , 2014, Immunological reviews.

[55]  H. Abken,et al.  Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma , 2014, Immunological reviews.

[56]  S. Ferrone,et al.  Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing , 2014 .

[57]  R. Davis,et al.  Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. , 2014, The Lancet. Oncology.

[58]  Jean J. Zhao,et al.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting , 2014, Nature Reviews Cancer.

[59]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[60]  B. Fox,et al.  OX40 is a potent immune-stimulating target in late-stage cancer patients. , 2013, Cancer research.

[61]  J. Wolchok,et al.  Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor , 2013, Cancer Immunology Research.

[62]  J. Wolchok,et al.  GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability , 2013, Cancer Immunology Research.

[63]  R. Swann,et al.  Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy , 2013, Clinical Cancer Research.

[64]  J. Wolchok,et al.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.

[65]  G. Dranoff,et al.  Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies , 2013, The Journal of experimental medicine.

[66]  R. Stahel,et al.  Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells , 2013, Journal of Translational Medicine.

[67]  Hao Liu,et al.  Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[68]  P. Darcy,et al.  Gene-engineered T cells for cancer therapy , 2013, Nature Reviews Cancer.

[69]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[70]  J. Wolchok,et al.  Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 , 2013, The Journal of experimental medicine.

[71]  N. Senzer,et al.  OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  J. Wolchok,et al.  Annals of the New York Academy of Sciences Development of Ipilimumab: a Novel Immunotherapeutic Approach for the Treatment of Advanced Melanoma , 2022 .

[73]  S. Rosenberg,et al.  Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia , 2013, The Journal of experimental medicine.

[74]  A. Korman,et al.  Role of the immunoglobulin constant region in the antitumor activity of antibodies to cytotoxic T-lymphocyte antigen-4 (CTLA-4). , 2013 .

[75]  R. A. Evans,et al.  CD40 immunotherapy for pancreatic cancer , 2013, Cancer Immunology, Immunotherapy.

[76]  A. Korman,et al.  Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells , 2013, Cancer Immunology Research.

[77]  J. Wolchok,et al.  Hepatotoxicity with combination of vemurafenib and ipilimumab. , 2013, The New England journal of medicine.

[78]  I. Salmon,et al.  Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma , 2013, Journal of immunotherapy.

[79]  K. Okkenhaug.  Signaling by the phosphoinositide 3-kinase family in immune cells. , 2013, Annual review of immunology.

[80]  D. Munn,et al.  Indoleamine 2,3 dioxygenase and metabolic control of immune responses. , 2013, Trends in immunology.

[81]  A. Hauschild,et al.  Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Sacha Gnjatic,et al.  The abscopal effect associated with a systemic anti-melanoma immune response. , 2013, International journal of radiation oncology, biology, physics.

[83]  J. Stagg,et al.  Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects , 2013, Therapeutic advances in medical oncology.

[84]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[85]  C. Klebanoff,et al.  Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy? , 2012, Journal of immunotherapy.

[86]  Irah L. King,et al.  Inhibition of Mechanistic Target of Rapamycin Promotes Dendritic Cell Activation and Enhances Therapeutic Autologous Vaccination in Mice , 2012, The Journal of Immunology.

[87]  W. Haining.  Thinking inside the box: how T cell inhibitory receptors signal , 2012, Nature Medicine.

[88]  Sheng Xiao,et al.  Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion , 2012, Nature Medicine.

[89]  H. Yoshiyama,et al.  Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 , 2012, Nature Immunology.

[90]  D. Olive,et al.  B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8+ T Cells in Patients After Allogeneic Stem Cell Transplantation , 2012, The Journal of Immunology.

[91]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[92]  P. O'dwyer,et al.  Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. , 2012 .

[93]  D. Munn,et al.  A phase I study of 1-methyl-D-tryptophan in patients with advanced malignancies. , 2012 .

[94]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[95]  A. Jha,et al.  Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. , 2012, Blood.

[96]  D. Hafler,et al.  The TIGIT/CD226 Axis Regulates Human T Cell Function , 2012, The Journal of Immunology.

[97]  A. Weinberg,et al.  Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression , 2012, PloS one.

[98]  Qingsheng Li,et al.  Regulating Mammalian Target of Rapamycin To Tune Vaccination-Induced CD8+ T Cell Responses for Tumor Immunity , 2012, The Journal of Immunology.

[99]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[100]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[101]  M. Horton,et al.  Regulation of immune responses by mTOR. , 2012, Annual review of immunology.

[102]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[103]  Karolina Palucka,et al.  Cancer immunotherapy via dendritic cells , 2012, Nature Reviews Cancer.

[104]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[105]  P. Palese,et al.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. , 2012, Future microbiology.

[106]  R. Levy,et al.  Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. , 2019, The Journal of clinical investigation.

[107]  Peter Vogel,et al.  Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .

[108]  Ornella Pagliano,et al.  CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. , 2012, Cancer research.

[109]  L. Boon,et al.  Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors. , 2012, Cancer research.

[110]  J. Moorman,et al.  Tim‐3 regulates pro‐ and anti‐inflammatory cytokine expression in human CD14+ monocytes , 2012, Journal of leukocyte biology.

[111]  S. Rosenberg,et al.  Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice , 2012, Clinical Cancer Research.

[112]  K. Flaherty,et al.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.

[113]  A. Arnold,et al.  Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. , 2011, International journal of oncology.

[114]  Peter D. Crompton,et al.  Therapeutic PD-L1 and LAG-3 blockade rapidly clears established blood-stage Plasmodium infection , 2011, Nature Immunology.

[115]  D. Munn.  Blocking IDO activity to enhance anti-tumor immunity. , 2012, Frontiers in bioscience.

[116]  T. Hahn,et al.  The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis , 2012, Cancer Immunology, Immunotherapy.

[117]  H. Abken,et al.  Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28‐OX40 signalling , 2011, International journal of cancer.

[118]  J. Wilmott,et al.  Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma , 2011, Clinical Cancer Research.

[119]  C. Rooney,et al.  Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[120]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[121]  Adrian P Gee,et al.  Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.

[122]  C. Ware,et al.  The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation , 2011, Immunological reviews.

[123]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[124]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[125]  S. Rosenberg,et al.  Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice , 2011, Clinical Cancer Research.

[126]  P. Foubert,et al.  Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. , 2011, Cancer cell.

[127]  A. Melcher,et al.  Thunder and lightning: immunotherapy and oncolytic viruses collide. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[128]  Pedro Romero,et al.  Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. , 2011, The Journal of clinical investigation.

[129]  M. Smyth,et al.  Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. , 2011, Cancer research.

[130]  Hao Liu,et al.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.

[131]  J. Allison,et al.  Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production , 2011, PloS one.

[132]  D. Munn,et al.  Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. , 2011, Blood.

[133]  H. Ott,et al.  Abstract 958: Treatment with a selective inhibitor of BRAFV600E increases melanocyte antigen expression and CD8 T cell infiltrate in tumors of patients with metastatic melanoma , 2011 .

[134]  Jeffrey T. Lau,et al.  CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma , 2011, Science Translational Medicine.

[135]  C. Robert,et al.  RAF inhibition and induction of cutaneous squamous cell carcinoma , 2011, Current opinion in oncology.

[136]  D. Gilham.  Effective adoptive T-cell therapy for cancer in the absence of host lymphodepletion. , 2011, Immunotherapy.

[137]  A. Cerwenka,et al.  Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity. , 2011, Vaccine.

[138]  Vijay K. Kuchroo,et al.  Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions , 2011, The Journal of Immunology.

[139]  C. Drake,et al.  LAG-3 in Cancer Immunotherapy. , 2011, Current topics in microbiology and immunology.

[140]  B. Baban,et al.  Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. , 2010, Immunity.

[141]  J. Wolchok,et al.  Anti-GITR antibodies--potential clinical applications for tumor immunotherapy. , 2010, Current opinion in investigational drugs.

[142]  Todd M. Allen,et al.  Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. , 2010, The Journal of clinical investigation.

[143]  S. Rosenberg,et al.  Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. , 2010, Blood.

[144]  James O. Jones,et al.  Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .

[145]  B. Fox,et al.  Signaling through OX40 enhances antitumor immunity. , 2010, Seminars in oncology.

[146]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[147]  A. Carè,et al.  A non‐redundant role for OX40 in the competitive fitness of Treg in response to IL‐2 , 2010, European journal of immunology.

[148]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[149]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[150]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[151]  G. Freeman,et al.  Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection , 2010, Proceedings of the National Academy of Sciences.

[152]  S. Rosenberg,et al.  Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. , 2010, Cancer research.

[153]  B. Taylor,et al.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.

[154]  M. Gutiérrez,et al.  First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity , 2010, Journal of Translational Medicine.

[155]  B. Kwon,et al.  Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice , 2010, PloS one.

[156]  L. Vaickus,et al.  Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR. , 2010 .

[157]  J. Allison,et al.  Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals , 2010, Clinical Cancer Research.

[158]  Tetsuya Shimizu,et al.  Combination of Adoptive Cell Transfer and Antibody Injection Can Eradicate Established Tumors in Mice–An in vivo study using anti-OX40mAb, anti-CD25mAb and anti-CTLA4mAb– , 2010, Immunopharmacology and immunotoxicology.

[159]  J. Wolchok,et al.  Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation , 2010, PloS one.

[160]  B. Vanhaesebroeck,et al.  The emerging mechanisms of isoform-specific PI3K signalling , 2010, Nature Reviews Molecular Cell Biology.

[161]  Qian Wang,et al.  Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. , 2010, Blood.

[162]  Lloyd J. Old,et al.  Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer , 2010, Proceedings of the National Academy of Sciences.

[163]  F. Powrie,et al.  OX40 is required for regulatory T cell–mediated control of colitis , 2010, The Journal of experimental medicine.

[164]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[165]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[166]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[167]  D. Schadendorf,et al.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.

[168]  Qingsheng Li,et al.  The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. , 2010, Immunity.

[169]  G. Freeman,et al.  T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells , 2010, The Journal of Immunology.

[170]  D. Olive,et al.  BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. , 2010, The Journal of clinical investigation.

[171]  Boquan Jin,et al.  A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions , 2010, Cellular and Molecular Immunology.

[172]  S. Kim-Schulze,et al.  Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma , 2010, Annals of Surgical Oncology.

[173]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[174]  S. Kim-Schulze,et al.  Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. , 2009, Cancer research.

[175]  N. Stanietsky,et al.  The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity , 2009, Proceedings of the National Academy of Sciences.

[176]  J. Wolchok,et al.  Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right , 2009, The Journal of Immunology.

[177]  L. Xerri,et al.  High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. , 2009, American journal of clinical pathology.

[178]  M. Azuma,et al.  Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. , 2009, International journal of oncology.

[179]  B. Escudier,et al.  A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[180]  S. Rosenberg,et al.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.

[181]  S. Sakaguchi,et al.  CD4+CD25−LAG3+ regulatory T cells controlled by the transcription factor Egr-2 , 2009, Proceedings of the National Academy of Sciences.

[182]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[183]  Russell G. Jones,et al.  Enhancing CD8 T-cell memory by modulating fatty acid metabolism , 2009, Nature.

[184]  H. Heslop,et al.  T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. , 2009, Blood.

[185]  D. Munn,et al.  Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. , 2009, Blood.

[186]  R. Ahmed,et al.  mTOR regulates memory CD8 T cell differentiation , 2009, Nature.

[187]  J. Wolchok,et al.  OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis , 2009, The Journal of experimental medicine.

[188]  T. Weichhart,et al.  The multiple facets of mTOR in immunity. , 2009, Trends in immunology.

[189]  A. Ganser,et al.  Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. , 2009, The Lancet. Oncology.

[190]  A. Thomson,et al.  Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.

[191]  K. Takeda,et al.  Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. , 2009, Blood.

[192]  J. Wolchok,et al.  Self-antigen–specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response , 2009, The Journal of experimental medicine.

[193]  R. Houot,et al.  T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. , 2009, Blood.

[194]  S. Rosenberg,et al.  Adoptive cell therapy for the treatment of patients with metastatic melanoma. , 2009, Current opinion in immunology.

[195]  M. Belvin,et al.  Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. , 2009, Cancer research.

[196]  R. Coombes,et al.  The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer , 2009, British Journal of Cancer.

[197]  P. van Endert,et al.  Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death , 2009, The EMBO journal.

[198]  B. Redman,et al.  Phase I/II trial of tremelimumab in patients with metastatic melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[199]  D. Arnott,et al.  B and T Lymphocyte Attenuator Regulates B Cell Receptor Signaling by Targeting Syk and BLNK , 2009, The Journal of Immunology.

[200]  P. Fournier,et al.  Newcastle Disease Virus: A Promising Vector for Viral Therapy, Immune Therapy, and Gene Therapy of Cancer , 2008, Methods in molecular biology.

[201]  H. Clark,et al.  The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells , 2009, Nature Immunology.

[202]  Antonio Polley,et al.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.

[203]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[204]  S. Sakaguchi,et al.  Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. , 2008, Cancer research.

[205]  N. Kawashima,et al.  Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells1 , 2008, The Journal of Immunology.

[206]  G. Freeman,et al.  Interaction of human PD-L1 and B7-1. , 2008, Molecular immunology.

[207]  K. Murphy,et al.  Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. , 2008, Arthritis and rheumatism.

[208]  S. Quezada,et al.  Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy , 2008, Immunological reviews.

[209]  L. Old,et al.  Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. , 2008, Cancer research.

[210]  Jianhong Cao,et al.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.

[211]  F. Moriyasu,et al.  Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab , 2008, International journal of cancer.

[212]  W. Leonard,et al.  IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. , 2008, Blood.

[213]  J. Kirkwood,et al.  Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) , 2008 .

[214]  K. Murphy,et al.  Regulatory T Cell Expression of Herpesvirus Entry Mediator Suppresses the Function of B and T Lymphocyte Attenuator-Positive Effector T Cells1 , 2008, The Journal of Immunology.

[215]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[216]  C. Liu,et al.  Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. , 2008, The Journal of clinical investigation.

[217]  G. Freeman,et al.  CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator , 2008, Nature Immunology.

[218]  David E. Anderson,et al.  Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells , 2007, Science.

[219]  C. Riccardi,et al.  Glucocorticoid-Induced TNFR-Related Protein Lowers the Threshold of CD28 Costimulation in CD8+ T Cells1 , 2007, The Journal of Immunology.

[220]  Lijun Xu,et al.  The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. , 2007, Cellular immunology.

[221]  D. Getnet,et al.  LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. , 2007, The Journal of clinical investigation.

[222]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[223]  A. Sharpe,et al.  Induction of autoimmune disease in CTLA-4−/− mice depends on a specific CD28 motif that is required for in vivo costimulation , 2007, Proceedings of the National Academy of Sciences.

[224]  S. Brandau,et al.  Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. , 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[225]  J. Weber.  Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. , 2007, The oncologist.

[226]  T. Okazaki,et al.  PD-1 and PD-1 ligands: from discovery to clinical application. , 2007, International immunology.

[227]  S. Russell,et al.  History of oncolytic viruses: genesis to genetic engineering. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[228]  Ralf-Holger Voss,et al.  Facilitating matched pairing and expression of TCR chains introduced into human T cells. , 2007, Blood.

[229]  M. Roberts,et al.  Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. , 2007, Current cancer drug targets.

[230]  G. Parmiani,et al.  Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 , 2007, The Journal of Immunology.

[231]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.

[232]  G. Bishop,et al.  TRAF proteins in CD40 signaling. , 2007, Advances in experimental medicine and biology.

[233]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.

[234]  P. Houghton,et al.  mTOR and cancer therapy , 2006, Oncogene.

[235]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[236]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[237]  W. Shi,et al.  Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. , 2006, Anticancer research.

[238]  M. Smyth,et al.  Eradication of established tumors in mice by a combination antibody-based therapy , 2006, Nature Medicine.

[239]  K. Sugamura,et al.  OX40-OX40 Ligand Interaction through T Cell-T Cell Contact Contributes to CD4 T Cell Longevity1 , 2006, The Journal of Immunology.

[240]  S. Rosenberg,et al.  Adoptive immunotherapy for cancer: building on success , 2006, Nature Reviews Immunology.

[241]  K. Hacène,et al.  A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. , 2006, Cancer letters.

[242]  T. Okazaki,et al.  The PD-1-PD-L pathway in immunological tolerance. , 2006, Trends in immunology.

[243]  K. Murphy,et al.  Cutting Edge: B and T Lymphocyte Attenuator and Programmed Death Receptor-1 Inhibitory Receptors Are Required for Termination of Acute Allergic Airway Inflammation1 , 2006, The Journal of Immunology.

[244]  E. Warren,et al.  Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. , 2006, Blood.

[245]  Daniel T. Fisher,et al.  Hurdles to Lymphocyte Trafficking in the Tumor Microenvironment: Implications for Effective Immunotherapy , 2006, Immunological investigations.

[246]  Pedro Romero,et al.  Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression , 2006, Immunologic research.

[247]  V. Kuchroo,et al.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.

[248]  T. Nomura,et al.  Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells , 2005, The Journal of experimental medicine.

[249]  T. Okazaki,et al.  Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[250]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[251]  S. Rosenberg,et al.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. , 2005, Human gene therapy.

[252]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[253]  B. Dörken,et al.  Costimulation by CD137/4–1BB inhibits T cell apoptosis and induces Bcl‐xL and c‐FLIPshort via phosphatidylinositol 3‐kinase and AKT/protein kinase B , 2005, European journal of immunology.

[254]  M. Colombo,et al.  Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. , 2005, Blood.

[255]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[256]  S. Paul,et al.  Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L , 2005, Cancer Gene Therapy.

[257]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[258]  T. Honjo,et al.  PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. , 2004, International immunology.

[259]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[260]  C. Ware,et al.  B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator , 2005, Nature Immunology.

[261]  G. Parmiani,et al.  A listing of human tumor antigens recognized by T cells: March 2004 update , 2005, Cancer Immunology, Immunotherapy.

[262]  Lieping Chen,et al.  Cutting Edge: Cbl-b: One of the Key Molecules Tuning CD28- and CTLA-4-Mediated T Cell Costimulation1 , 2004, The Journal of Immunology.

[263]  Y. Okayama,et al.  T Cell Proliferation by Direct Cross-Talk between OX40 Ligand on Human Mast Cells and OX40 on Human T Cells: Comparison of Gene Expression Profiles between Human Tonsillar and Lung-Cultured Mast Cells1 , 2004, The Journal of Immunology.

[264]  C. Drake,et al.  Role of LAG-3 in regulatory T cells. , 2004, Immunity.

[265]  A. Houghton,et al.  Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.

[266]  L. Lanier,et al.  Cross-Talk between Activated Human NK Cells and CD4+ T Cells via OX40-OX40 Ligand Interactions1 , 2004, The Journal of Immunology.

[267]  L. Young,et al.  The role of the CD40 pathway in the pathogenesis and treatment of cancer. , 2004, Current opinion in pharmacology.

[268]  H. Simon,et al.  Functional expression of CD134 by neutrophils , 2004, European journal of immunology.

[269]  M. Serafini,et al.  Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. , 2004, Human gene therapy.

[270]  M. Brenner,et al.  Genetic modification of T lymphocytes for adoptive immunotherapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[271]  I. Ishikawa,et al.  Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells1 , 2004, The Journal of Immunology.

[272]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[273]  Lieping Chen,et al.  Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens , 2004, International journal of cancer.

[274]  In-Jeong Kim,et al.  Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In Vivo1 , 2004, The Journal of Immunology.

[275]  K. Sugamura,et al.  Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. , 2004, Cancer research.

[276]  Qingsheng Li,et al.  NK and CD8+ T cell‐mediated eradication of poorly immunogenic B16‐F10 melanoma by the combined action of IL‐12 gene therapy and 4‐1BB costimulation , 2004, International journal of cancer.

[277]  M. Croft,et al.  Costimulation of CD8 T Cell Responses by OX401 , 2004, The Journal of Immunology.

[278]  Tomoki Ito,et al.  Plasmacytoid Dendritic Cells Regulate Th Cell Responses through OX40 Ligand and Type I IFNs1 , 2004, The Journal of Immunology.

[279]  K. Sugamura,et al.  Distinct Roles for the OX40-OX40 Ligand Interaction in Regulatory and Nonregulatory T Cells1 , 2004, The Journal of Immunology.

[280]  G. Mufti,et al.  Role of 4-1BB:4-1BB ligand in cancer immunotherapy , 2004, Cancer Gene Therapy.

[281]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[282]  L. Young,et al.  Inhibition of Phosphatidylinositol 3-Kinase- and ERK MAPK-regulated Protein Synthesis Reveals the Pro-apoptotic Properties of CD40 Ligation in Carcinoma Cells* , 2004, Journal of Biological Chemistry.

[283]  A. Lawson,et al.  Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain , 2004, The Journal of Immunology.

[284]  M. Serafini,et al.  Elongation factor 1 (EF1alpha) promoter in a lentiviral backbone improves expression of the CD20 suicide gene in primary T lymphocytes allowing efficient rituximab-mediated lysis. , 2004, Haematologica.

[285]  D. Munn,et al.  IDO and tolerance to tumors. , 2004, Trends in molecular medicine.

[286]  P. Gaulard,et al.  Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand , 2004, Immunogenetics.

[287]  Michel C Nussenzweig,et al.  Tolerogenic dendritic cells. , 2003, Annual review of immunology.

[288]  Jessie-F. Fecteau,et al.  CD40 Stimulation of Human Peripheral B Lymphocytes: Distinct Response from Naive and Memory Cells1 , 2003, The Journal of Immunology.

[289]  J. Cheville,et al.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.

[290]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[291]  S. Rosenberg,et al.  High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens , 2003, The Journal of Immunology.

[292]  Steven A. Rosenberg,et al.  Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.

[293]  J. Allison,et al.  BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 , 2003, Nature Immunology.

[294]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[295]  J. Blattman,et al.  Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. , 2003, Cancer cell.

[296]  Michel Sadelain,et al.  Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.

[297]  D. Vignali,et al.  Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-31 , 2002, The Journal of Immunology.

[298]  D. Pardoll,et al.  Expression of Programmed Death 1 Ligands by Murine T Cells and APC1 , 2002, The Journal of Immunology.

[299]  K. Sugamura,et al.  Consequences of OX40‐OX40 ligand interactions in Langerhans cell function: enhanced contact hypersensitivity responses in OX40L‐transgenic mice , 2002, European journal of immunology.

[300]  Sujung Park,et al.  4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-11 , 2002, The Journal of Immunology.

[301]  M. Meseck,et al.  OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[302]  A. Sharpe,et al.  Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation , 2002, European journal of immunology.

[303]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[304]  V. Kuchroo,et al.  Inhibition of CTLA-4 Function by the Regulatory Subunit of Serine/Threonine Phosphatase 2A1 , 2002, The Journal of Immunology.

[305]  Jiang Zhu,et al.  Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. , 2002, The Journal of clinical investigation.

[306]  Lieping Chen,et al.  Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells1 , 2002, The Journal of Immunology.

[307]  J. Shimizu,et al.  Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.

[308]  Tatyana Chernova,et al.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease , 2002, Nature.

[309]  T. Okazaki,et al.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[310]  Hans J. Stauss,et al.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer , 2001, Nature Immunology.

[311]  P. Rogers,et al.  OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. , 2001, Immunity.

[312]  B. Seliger,et al.  T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. , 2001, Cancer research.

[313]  T. Clackson,et al.  A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. , 2001, Blood.

[314]  A. Sharpe,et al.  CTLA-4 regulates induction of anergy in vivo. , 2001, Immunity.

[315]  E. Jonasch,et al.  Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. , 2001, The oncologist.

[316]  T. Okazaki,et al.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.

[317]  Craig W. Reynolds,et al.  Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. , 2001, Blood.

[318]  M. V. Heiden,et al.  The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. , 2000, Immunity.

[319]  T. Mak,et al.  Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.

[320]  Fiona Powrie,et al.  Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation , 2000, The Journal of experimental medicine.

[321]  T. Barbui,et al.  Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. , 2000, Human gene therapy.

[322]  P. Dalerba,et al.  Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[323]  G. Alvord,et al.  Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.

[324]  J. Becker,et al.  Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells , 2000, Cancer Gene Therapy.

[325]  J. Banchereau,et al.  CD40‐CD40 ligand , 2000, Journal of leukocyte biology.

[326]  K. Beutner,et al.  Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. , 1999, Journal of the American Academy of Dermatology.

[327]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[328]  E. Gilboa.  The makings of a tumor rejection antigen. , 1999, Immunity.

[329]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[330]  Philip R. Cohen,et al.  Paradoxical activation of Raf by a novel Raf inhibitor. , 1999, Chemistry & biology.

[331]  R. Edelson.  Sézary syndrome, cutaneous T-cell lymphoma, and extracorporeal photopheresis. , 1999, Archives of dermatology.

[332]  J. Inoue,et al.  Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[333]  A. Weinberg,et al.  Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. , 1999, Journal of immunology.

[334]  J. Bluestone,et al.  Molecular basis of T cell inactivation by CTLA-4. , 1998, Science.

[335]  P. Gregersen,et al.  A 15-Year Follow-up of AJCC Stage III Malignant Melanoma Patients Treated Postsurgically with Newcastle Disease Virus (NDV) Oncolysate and Determination of Alterations in the CD8 T Cell Repertoire , 1998, Molecular medicine.

[336]  Shannon R. Magari,et al.  Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[337]  W. Meyers,et al.  Laparoscopic surgery and the systemic immune response. , 1998, Annals of surgery.

[338]  Yuetsu Tanaka,et al.  Expression and function of OX40 ligand on human dendritic cells. , 1997, Journal of immunology.

[339]  K. Bland,et al.  Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. , 1997, Annals of surgery.

[340]  A. Aruffo,et al.  4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses , 1997, The Journal of experimental medicine.

[341]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[342]  R. Geha,et al.  Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. , 1997, Immunity.

[343]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[344]  A. Barclay,et al.  OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand , 1996, European journal of immunology.

[345]  Antonio Lanzavecchia,et al.  T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds , 1996, Science.

[346]  J. Bluestone,et al.  Regulation of CTLA-4 expression during T cell activation. , 1996, Journal of immunology.

[347]  J. Bluestone,et al.  CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301] , 1996, The Journal of experimental medicine.

[348]  J. Allison,et al.  CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells , 1996, The Journal of experimental medicine.

[349]  T. Mak,et al.  Regulation of T Cell Receptor Signaling by Tyrosine Phosphatase SYP Association with CTLA-4 , 1996, Science.

[350]  Yuetsu Tanaka,et al.  The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells , 1996, The Journal of experimental medicine.

[351]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[352]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[353]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[354]  D. Bruniquel,et al.  CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins , 1995, European journal of immunology.

[355]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[356]  H. P. Fell,et al.  Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. , 1995, Immunity.

[357]  M. Seldin,et al.  Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV‐1‐regulated protein gp34. , 1994, The EMBO journal.

[358]  Craig W. Reynolds,et al.  Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? , 1994, Blood.

[359]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[360]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[361]  S. Schreiber,et al.  Controlling signal transduction with synthetic ligands. , 1993, Science.

[362]  R. Callard,et al.  CD40 ligand and its role in X-linked hyper-IgM syndrome. , 1993, Immunology today.

[363]  M. Horowitz,et al.  Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose , 1993 .

[364]  D. Murray,et al.  A ten-year follow-up on stage II Malignant Melanoma patients treated postsurgically with newcastle disease virus oncolysate , 1992, Medical oncology and tumor pharmacotherapy.

[365]  C. Auffray,et al.  Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens , 1992, The Journal of experimental medicine.

[366]  W. Coley.  The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .

[367]  J. Sprent,et al.  Extrathymic tolerance of mature T cells: Clonal elimination as a consequence of immunity , 1990, Cell.

[368]  R. Schwartz,et al.  A cell culture model for T lymphocyte clonal anergy. , 1990, Science.

[369]  A. Barclay,et al.  Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes‐‐a molecule related to nerve growth factor receptor. , 1990, The EMBO journal.

[370]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[371]  Murray Dr,et al.  Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate. , 1988 .

[372]  D. Paterson,et al.  Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. , 1987, Molecular immunology.

[373]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[374]  R. North.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.

[375]  P. Klein,et al.  VIRAL ONCOLYSIS: INCREASED IMMUNOGENICITY OF HOST CELL ANTIGEN ASSOCIATED WITH INFLUENZA VIRUS , 1967, The Journal of experimental medicine.